![Navigating HCM Management Paradigms with Dr Masri](https://assets.radcliffecardiology.com/s3fs-public/podcast/2024-03/DELV-15825_BMS_Parallax_2_SoundCloud_3000x3000.png?VersionId=0Dh9nThLYDcxU3M3Hi60JwULAmGYE_M.)
In the second episode of our mini-series "Conversations about Hypertrophic Cardiomyopathy", Dr Ankur Kalra sat down with Dr Ahmad Masri to have a deep-dive into the management paradigms of hypertrophic cardiomyopathy (HCM), considering the evolution of medical therapy in recent years. Dr Ahmad Masri is a Cardiologist and the Director of OHSU Hypertrophic Cardiomyopathy Center.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
Dr Kalra invites Dr Masri to guide us through his decision-making process in evaluating medical and surgical options in patients with obstructive hypertrophic cardiomyopathy. Dr Masri delves into first and second-line treatment strategies while exploring the significance of FDA-approved cardiac myosin inhibitors in the management of hypertrophic cardiomyopathy. Dr Kalra asks Dr Masri about the practical office-based clinical course for patients deemed suitable candidates to receive mavacamten. Dr Masri provides a clear and practical outline of what it entails to opt for this second-line medical therapy including the REMS programme required for therapy (www.camzyosrems.com). Dr Masri highlights the importance of looking at HCM patients holistically to find the treatment which best fits their circumstances and preferences in choosing surgical and medical therapy options.
What are the available management options for patients with HCM? How does Dr Masri approach shared decision-making in the management of HCM? What are some of the practical considerations regarding the cardiac myosin inhibitor, mavacamten?
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb.
![Differential Diagnosis, Genetic Testing & Patient-centric Therapy](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2023-08/DELV-15829_BMS_Parallax_3_Web_1920x1080.png?VersionId=s6RsjLZdRYXdnrtYaEXo7RwaeF9v0bhY&itok=CjbIDDw-)
Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
![EP 117: Transforming Cardiac Surgery Recovery: Evidence-Based Insights with Dr Gerdisch](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-08/DELV-23187_IND_Parallax_EP117_Gerdisch_Web_1920x1080.jpg?VersionId=10jQcg6sZufXOZ_V2.eXBcL2gcTGQckL&itok=QUtGQF0H)
Dr Gerdisch shares insights into his research on rigid sternal fixation and enhanced recovery protocols, which have shown promising results in postoperative pain management and patient recovery.
![EP 116: Navigating the Realities of Guideline Directed Medical Therapy with Dr Chahoud and Dr Israel](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-07/DELV-17584_ZOLL_Parallax_3_Web_1920x1080_0.jpg?VersionId=7AsAfHb6JltTsIeGvFIL8PjSD_bJZQC7&itok=dAPVGO1r)
![EP 115: Navigating Cultures and Cardiology: Dr Janarthanan Sathananthan's Global Journey](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-07/DELV-22085_IND_Parallax_EP116_Sathananthan_Web_1920x1080.jpg?VersionId=X7UeGqRVZ0MB.gLJ_K0aoLflMIJqb8X.&itok=QOEUH6cW)
![The Leap Year Gene with Shelley Wood, Bestselling Author & Editor-in-Chief of TCTmd](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-06/DELV-21301_Parallax_EP114_Wood_Web_1920x1080.jpg?VersionId=o3p3VftF1kaRvWNWKzolgCRXyALPXFHt&itok=H2D2X7SD)
![EP 113: Your Guide to Radiation Hygiene: Insights from Manufacturer and Users](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-06/DELV-21795_Parallax_EP113_Breininger_Radtke_Web_1920x1080.jpg?VersionId=3d524UUeTRRuHi6Y8NqMN5n1WUksM6HI&itok=Eh3lMH-C)
![EP 112: Just One Heart: Burnout, Positive Mindset & Leadership with Dr Fisher](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-05/DELV-21579_Parallax_EP112_Fisher_Web_1920x1080.jpg?VersionId=NH6WDl3W2YJSM8.eRkQN4vq5MY2xbfEd&itok=tVbLnj0V)
![EP 111: ACC 24 in Review With Dr Vallabhajosyula: 5 Trials That Will Change Your Practice](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-04/DELV-21011_Parallax_EP111_Vallabhajosyula_Web_1920x1080.jpg?VersionId=ZOcxXpbfxpQgrVCl9j7I92zCplTgt1mZ&itok=LmOEuJkd)
![EP 110: Cultivating Leadership, Civic Duty & the Presidential Leadership Programme with Dr Sinha](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-04/DELV-20782_IND_Parallax_Sinha_Web_1920x1080-2.png?VersionId=o5_ez0NqChSi.6qI0.I0LGPQ4LmwK.Ac&itok=jmdoA2eD)
![EP 109: Navigating Volume Status in Heart Failure Patients with Dr Andrew Darlington](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/DELV-17583_ZOLL_Parallax_2_Web_1920x1080.jpg?VersionId=bavAruPc_yuREgwZwQomlSmR8bzSje6U&itok=ybL6yurd)
Together, Dr Kalra and Dr Darlington delve into the significance of assessing volume status in patients with heart failure, highlighting its continued relevance in 2024, including the availability of new diagnostic tools, including the Heart Failure Management System (HFMS).
This series is supported by ZOLL and is intended for Health Care Professionals.
![EP 108: Song of Our Scars: Authorship & Medicine with Senior Advisor for FDA, Dr Warraich](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/DELV-19380_IND_Parallax_EP108_Warraich_Web_1920x1080.jpg?VersionId=HPs.636T_kpikJm7DK8VEDs5f0aphHbL&itok=Nh_OhD_E)
![High-Sensitivity Cardiac Troponin ACS](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_0.png?VersionId=uAw7s0xUwfjE1_1xcLbM7odh7YHQJw7K&itok=pSrlvyyg)
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/Parallax_01_1200x628.jpg?VersionId=8YtGXyCvpISHGUAWuUfXgEArl7M4TInv&itok=fTCIJSke)